Development
DexCom, Inc.
DXCM
$82.26
$1.642.03%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 24.49% | 21.85% | 19.61% | 17.50% | 18.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.49% | 21.85% | 19.61% | 17.50% | 18.84% |
| Cost of Revenue | 29.87% | 25.65% | 27.23% | 28.33% | 33.68% |
| Gross Profit | 21.55% | 19.80% | 15.70% | 12.27% | 12.06% |
| SG&A Expenses | 17.63% | 26.26% | 25.76% | 29.35% | 24.82% |
| Depreciation & Amortization | -- | -107.04% | -106.06% | -103.85% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.09% | 14.66% | 12.86% | 13.60% | 15.39% |
| Operating Income | 52.79% | 90.02% | 88.95% | 52.03% | 47.18% |
| Income Before Tax | 81.78% | 126.29% | 118.97% | 66.61% | 52.18% |
| Income Tax Expenses | 240.52% | 1,007.54% | 36,525.00% | 2,177.05% | 24.31% |
| Earnings from Continuing Operations | 58.70% | 54.44% | 55.30% | 13.50% | 57.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.70% | 54.44% | 55.30% | 13.50% | 57.31% |
| EBIT | 52.79% | 90.02% | 88.95% | 52.03% | 47.18% |
| EBITDA | 43.25% | 68.96% | 70.49% | 54.47% | 56.40% |
| EPS Basic | 60.18% | 55.83% | 55.98% | 13.28% | 56.37% |
| Normalized Basic EPS | 82.92% | 128.36% | 119.80% | 65.90% | 51.17% |
| EPS Diluted | 59.03% | 54.45% | 55.92% | 14.70% | 56.93% |
| Normalized Diluted EPS | 82.22% | 124.50% | 118.31% | 67.93% | 52.28% |
| Average Basic Shares Outstanding | -0.86% | -0.83% | -0.47% | 0.26% | 0.65% |
| Average Diluted Shares Outstanding | -0.53% | 2.33% | 2.00% | 1.05% | 2.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |